Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    UNIS logo
    Cerus Corporation logo featuring a red circle with a stylized stylized red blood cell within it and the text 30 Years below

    Cerus Corporation

    Cerus Corporation is a biotechnology leader dedicated to safeguarding the world’s blood supply through innovative pathogen reduction technologies, serving blood centers and hospitals globally.

    Company Overview

    Cerus Corporation is a biotechnology company specializing in blood safety solutions, with a primary focus on developing and supplying pathogen-protected blood components. Headquartered in Concord, California, Cerus serves blood centers, hospitals, and patients worldwide. Its flagship INTERCEPT Blood System is a market leader in pathogen reduction for platelets and plasma.

    Key Metrics

    250

    Import Shipments

    3

    Distribution Centers

    75.0M

    Annual Revenue

    1991

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    Cerus Corporation is likely focused on expanding global adoption of its INTERCEPT Blood System, advancing new product innovations, and strengthening its supply chain to meet growing demand for safe blood products.

    Strategic Expansion

    Achieved CE mark approval for the INT200 next-generation LED-based illumination device.

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Cerus Corporation develops, manufactures, and markets advanced technologies to enhance the safety of blood transfusions. Its core product, the INTERCEPT Blood System, is designed to inactivate a broad spectrum of pathogens in platelets and plasma, reducing the risk of transfusion-transmitted infections. Cerus collaborates with leading blood centers and hospitals in over 40 countries, supporting the treatment of millions of patients annually. The company is also advancing new technologies, including next-generation devices and systems for red blood cells.

    Headquarters

    Concord, California, United States

    Founded

    1991

    Stock Symbol

    CERS